Loading patent…
AssigneeOncolytics Biotech Inc.
InventorsPatrick W. K. Lee, James Strong, Matthew C. Coffey
Estimating the term…
Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
A method of treating a ras-mediated proliferative disorder in an immunocompetent mammal, comprising administering to the proliferating cells in said mammal an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells, wherein the one or more reoviruses is immunoprotected.
A method of treating a ras-mediated proliferative disorder in a mammal comprising administering to the ras-mediated proliferating cells of the mammal an effective amount of one or more immunioprotected reoviruses under conditions which result in substantial lysis of the ras-mediated proliferating cells.
Dependencies are inferred from the claim text.